MA34724B1 - Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase - Google Patents

Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase

Info

Publication number
MA34724B1
MA34724B1 MA35980A MA35980A MA34724B1 MA 34724 B1 MA34724 B1 MA 34724B1 MA 35980 A MA35980 A MA 35980A MA 35980 A MA35980 A MA 35980A MA 34724 B1 MA34724 B1 MA 34724B1
Authority
MA
Morocco
Prior art keywords
enkephalinase
inhibitor
administration
novel form
novel
Prior art date
Application number
MA35980A
Other languages
English (en)
Inventor
Jean-Stephane Julien
Marc Maury
Jeanne-Marie Lecomte
Xavier Ligneau
Philippe Robert
Jean-Charles Schwartz
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of MA34724B1 publication Critical patent/MA34724B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une nouvelle formulation d'un inhibiteur de l'enképhalinase, tel que le racécadotril ou le dexécadotril, le procédé de préparation associé, et son utilisation dans le traitement de la diarrhée.
MA35980A 2010-12-10 2013-06-06 Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase MA34724B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10306397A EP2462922A1 (fr) 2010-12-10 2010-12-10 Nouvelle forme d'administration pour inhibiteurs de l'enképhalinase
PCT/EP2011/072315 WO2012076691A1 (fr) 2010-12-10 2011-12-09 Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase

Publications (1)

Publication Number Publication Date
MA34724B1 true MA34724B1 (fr) 2013-12-03

Family

ID=45092498

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35980A MA34724B1 (fr) 2010-12-10 2013-06-06 Nouvelle forme d'administration d'un inhibiteur de l'enképhalinase

Country Status (32)

Country Link
US (1) US9439853B2 (fr)
EP (2) EP2462922A1 (fr)
JP (1) JP5847192B2 (fr)
KR (1) KR101837685B1 (fr)
CN (1) CN103338749B (fr)
AP (1) AP3787A (fr)
AU (1) AU2011340500B2 (fr)
BR (1) BR112013014388A2 (fr)
CA (1) CA2820835C (fr)
CO (1) CO6731092A2 (fr)
CY (1) CY1123056T1 (fr)
DK (1) DK2648696T3 (fr)
EA (1) EA022730B1 (fr)
EC (1) ECSP13012665A (fr)
ES (1) ES2791710T3 (fr)
HR (1) HRP20200555T1 (fr)
HU (1) HUE049273T2 (fr)
IL (1) IL226775A (fr)
LT (1) LT2648696T (fr)
MA (1) MA34724B1 (fr)
ME (1) ME03769B (fr)
MX (1) MX354858B (fr)
NZ (1) NZ611597A (fr)
PL (1) PL2648696T3 (fr)
PT (1) PT2648696T (fr)
RS (1) RS60197B1 (fr)
SG (1) SG191068A1 (fr)
SI (1) SI2648696T1 (fr)
SM (1) SMT202000229T1 (fr)
TN (1) TN2013000239A1 (fr)
UA (1) UA111835C2 (fr)
WO (1) WO2012076691A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2987268B1 (fr) 2012-02-28 2014-07-11 Ammtek Formulations liquides de sulfamides hypoglycemiants
EP2866789B1 (fr) 2012-06-28 2018-08-01 Johnson & Johnson Consumer Inc. Compositions lipidiques de racécadotril
US9114171B2 (en) * 2012-06-28 2015-08-25 Mcneil-Ppc, Inc. Racecadotril liquid compositions
US9801819B2 (en) 2012-06-28 2017-10-31 Johnson & Johnson Consumer Inc. Racecadotril compositions
PT2866802T (pt) * 2012-06-28 2016-09-05 Johnson & Johnson Consumer Inc Composições líquidas racecadotril
CN105848643A (zh) * 2013-12-23 2016-08-10 强生消费者公司 消旋卡多曲组合物
EP2918268A1 (fr) 2014-03-10 2015-09-16 Galenicum Health S.L. Compositions pharmaceutiques comprenant un agent actif
ES2555484T1 (es) 2014-05-26 2016-01-04 Galenicum Health S.L. Composiciones farmacéuticas que contienen un agente activo
MA40859A (fr) 2014-10-29 2017-09-05 Johnson & Johnson Consumer Inc Particules de cadotril
CN105125477A (zh) * 2015-08-19 2015-12-09 黑龙江佰彤儿童药物研究有限公司 一种含消旋卡多曲的药物制剂及制备方法
IT201700099690A1 (it) 2017-09-06 2019-03-06 Abiogen Pharma Spa Composizione per l’integrazione di calcio

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
GB0015490D0 (en) * 2000-06-23 2000-08-16 Smithkline Beecham Lab Novel formulations
DK1294372T3 (da) 2000-06-23 2005-09-19 Bioprojet Soc Civ Törpulverformulering der omdanner racecadotril
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
EP1563848A1 (fr) * 2004-02-12 2005-08-17 Bioprojet Nouvelles combinaisons d' agents antiémétiques avec inhibiteurs de l'enképhalinase
WO2007102171A2 (fr) * 2006-03-07 2007-09-13 Panacea Biotec Ltd Nouveaux sels de l'acide 1h-1-benzazépine-1-acétique, préparation de ceux-ci et composition pharmaceutique comprenant ceux-ci
CN101103960B (zh) * 2006-07-14 2010-12-08 海南盛科生命科学研究院 一种含有消旋卡多曲的干混悬剂及其制备方法
TW201014830A (en) 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Also Published As

Publication number Publication date
DK2648696T3 (da) 2020-05-04
AU2011340500B2 (en) 2016-10-20
CA2820835A1 (fr) 2012-06-14
AP2013006971A0 (en) 2013-07-31
ECSP13012665A (es) 2013-08-30
JP5847192B2 (ja) 2016-01-20
MX2013006492A (es) 2013-11-01
JP2014503512A (ja) 2014-02-13
PL2648696T3 (pl) 2020-07-27
UA111835C2 (uk) 2016-06-24
ES2791710T3 (es) 2020-11-05
ME03769B (fr) 2021-04-20
HRP20200555T1 (hr) 2020-07-24
PT2648696T (pt) 2020-05-13
HUE049273T2 (hu) 2020-09-28
KR20130124335A (ko) 2013-11-13
AU2011340500A1 (en) 2013-06-27
MX354858B (es) 2018-03-23
BR112013014388A2 (pt) 2016-09-27
EP2462922A1 (fr) 2012-06-13
EP2648696A1 (fr) 2013-10-16
NZ611597A (en) 2015-01-30
EA201300688A1 (ru) 2014-11-28
US20130331423A1 (en) 2013-12-12
US9439853B2 (en) 2016-09-13
WO2012076691A1 (fr) 2012-06-14
LT2648696T (lt) 2020-05-11
AP3787A (en) 2016-08-31
KR101837685B1 (ko) 2018-03-12
TN2013000239A1 (en) 2014-11-10
EA022730B1 (ru) 2016-02-29
CA2820835C (fr) 2019-01-08
CN103338749B (zh) 2017-04-26
EP2648696B1 (fr) 2020-02-19
CO6731092A2 (es) 2013-08-15
SMT202000229T1 (it) 2020-07-08
IL226775A (en) 2017-09-28
CN103338749A (zh) 2013-10-02
CY1123056T1 (el) 2021-10-29
SG191068A1 (en) 2013-07-31
SI2648696T1 (sl) 2020-07-31
RS60197B1 (sr) 2020-06-30

Similar Documents

Publication Publication Date Title
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA33000B1 (fr) Dicyanopyridine a substitution alkylamino et ses promedicaments d'ester d'acide amine
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA34753B1 (fr) Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA33358B1 (fr) Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
MA20150279A1 (fr) (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel
MA34837B1 (fr) Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla)
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
TN2013000353A1 (fr) Dérivés de fluoro-pyridinone utiles comme agents antibactériens
MA37886B1 (fr) Nouvelles pyridinones bicycliques
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
EP2572721A4 (fr) Composition pharmaceutique comprenant un inhibiteur de hif-2 comme ingrédient actif pour la prévention ou le traitement de l'arthrite
MA35638B1 (fr) 2-thiopyrimidinones
EA201300688A1 (ru) Новая форма введения ингибитора энкефалиназы
TN2011000669A1 (fr) L-serine pour son utilisation en tant que medicament pour prevenir et/ou traiter une reaction inflammatoire de la peau
EA201591180A1 (ru) Составы ингибитора lfa-1
MA35937B1 (fr) Composés substitués de chromane en tant que modulateurs des récepteurs de détection du calcium
AR098899A1 (es) Composiciones para el cuidado oral y métodos
MX335945B (es) Composicion antifungica novedosa.
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
MA39496A (fr) Inhibiteurs de mtor spécifiques dans le traitement de l'adrénoleucodystrophie liée à l'x